Blockchain Registration Transaction Record

BioCorRx Inc. Acquires LUCEMYRA, an FDA-Approved Opioid Withdrawal Medication

BioCorRx Inc. acquires LUCEMYRA, an FDA-approved opioid withdrawal medication, expanding treatment options for patients. The acquisition signifies a strategic move to drive revenue growth and enhance shareholder value. With a focus on developing innovative solutions for substance use disorders, BioCorRx Pharmaceuticals Inc. aims to address critical public health challenges like methamphetamine use disorder.

This news highlights the acquisition of LUCEMYRA by BioCorRx Inc., marking a significant development in the treatment of opioid withdrawal. The availability of non-opioid medication like LUCEMYRA offers a crucial solution for patients undergoing opioid detoxification. Additionally, the ongoing research for sustained-release naltrexone products demonstrates BioCorRx's commitment to addressing substance use disorders and improving treatment options.